Oxidative stress, inflammation, endothelial function, blood pressure and lipid profile
Conditions
Interventions
Group 1 (control): not coffee consumption
Group 2 (Study): coffee consumption of two cups of coffee A per day, each cup of 200 mL (oral administration), during 8 weeks
Group 3 (Study): coffee consumpt
Sponsors
(Vidarium) Vidarium, research center on nutrition health and wellness
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Aged = 18 and = 60 years 2. Body mass index (BMI) between 18.8 kg/m2 and 30 kg/m2 up. 3. Habitual coffee drinkers: consumption in the last year of three or more cups / day. 4. No smokers. 5. No highly competitive sportspeople (subjects with a sedentary physical activity, mild or moderate will be included, in no case exceeding 10 hours per week of training). 6. No history and / or diagnosis of chronic diseases (heart attack, hypertension, congestive heart failure, stroke, arrhythmia, dyslipidemia, diabetes mellitus, cancer, chronic renal failure, hepatic dysfunction, hypothyroidism, insomnia, duodenal ulcer, gastritis, malabsorption syndrome, dysautonomia, sleep disturbances and psychiatric disorders). 7. No consumption of drugs: Hypolipidemic agent, antioxidant supplements, anticonvulsants, anti-inflammatories, steroids, psychiatric drugs, hormone replacement therapy. 8. With a maximum of 10 alcohol drinks per week for women and 15 for men. 9. Having a work schedule between 7.00 am and 6.00 pm Monday to Friday and not have to leave the institution during the study.
Exclusion criteria
Exclusion criteria: 1. Women who are pregnant or breastfeeding. 2. Vegetarians. 3. Subjects with secondary symptoms to coffee consumption.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma levels of caffeic acid and ferulic acid (quantitative determination in nmol/L by chromatography). Measurement time: at baseline, 1 hour after the first consumption, 8 weeks after the inclusion. Total antioxidant capacity (umol-equ-TROLOX/L plasma values measured by FRAP and TRAP methods). Measurement time: at baseline, 1 hour after the first consumption, 8 weeks after the inclusion. Delay in LDL oxidation ((lipid peroxidation), LDL oxidation Lag time in seconds). Measurement time: at baseline, 8 weeks after the inclusion. | — |
Secondary
| Measure | Time frame |
|---|---|
| Isoprostanes levels (in ng/mg creatinine by chromatography). Measurement time: at baseline, 8 weeks after the inclusion. High Sensitive C-reactive protein ((Hs-CRP). Guidelines according to AHA/CDC (1.0 persistent elevations may represent non-cardiovascular inflammation)). Measurement time: at baseline, 8 weeks after the inclusion. Fibrinogen (measured in mg% by nephelometry). Measurement time: at baseline, 8 weeks after the inclusion. Total cholesterol (Colorimetric assay (mg/dL)). Measurement time: at baseline,8 weeks after the inclusion. cLDL, (enzymatic assay (mg/dL)). Measurement time: at baseline, 8 weeks after the inclusion. cHDL (enzymatic assay (mg/dL)). Measurement time: at baseline, 8 weeks after the inclusion. Triglycerides (Colorimetric assay (mg/dL)). Measurement time: at baseline, 8 weeks after the inclusion. Endothelial function (Flow mediated dilation test of brachial artery (% of change)). Measurement time: at baseline, 8 weeks after the inclusion. Nitric oxide metabolites (Colorimetric kit (uM)). Measurement time: at baseline, 8 weeks after the inclusion. Blood pressure (Standardized technique according to AHA and European Association of Cardiology (mmHg)). Measurement time: at baseline, 8 weeks after the inclusion. | — |
Countries
Colombia
Contacts
Public ContactGloria Agudelo Ochoa
Vidarium, centro de investigación en nutrición, salud y bienestar. Grupo Empresarial Nutresa
Outcome results
None listed